Week In Review: $1.7 Billion Collaboration Between Elpiscience And Astellas Is Final 2023 Deal

Shanghai’s Elpiscience Biopharma has formed a $1.7 billion collaboration with Japan’s Astellas Pharma to develop a novel bispecific macrophage engager, ES019, along with an unspecified program. Initially, Elpiscience will receive up to $37 million.